Brad Windle

发表

Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.

S. Grossman, S. Deb, S. Deb, 2012, Genes & cancer.

Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter

S. Grossman, S. Deb, S. Deb, 2016, Oncotarget.

Sorting Nexin 5 Controls Head and Neck Squamous Cell Carcinoma Progression by Modulating FBW7

B. Windle, Bin Hu, Guoping Li, 2019, Journal of Cancer.

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy

J. Arribas, C. Costa, H. Harada, 2018, Proceedings of the National Academy of Sciences.

Wild-type p53 and p73 negatively regulate expression of proliferation related genes

M. Anderson, M. Scian, K. Stagliano, 2008, Oncogene.

Gain‐of‐function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells

S. Grossman, S. Deb, S. Deb, 2017, Molecular oncology.

ChIP sequencing to identify p53 targets.

S. Deb, C. Vaughan, Brad Windle, 2013, Methods in molecular biology.

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

Krista M. Powell, Y. Yatabe, H. Harada, 2018, Clinical Cancer Research.

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

S. Ramaswamy, M. Rivera, T. Jacks, 2015, Proceedings of the National Academy of Sciences.

Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells.

S. Deb, S. Deb, W. A. Yeudall, 2011, Genes & cancer.

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

B. Bernstein, Y. Drier, L. Sequist, 2017, Clinical Cancer Research.

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

U. McDermott, M. Garnett, A. Dastur, 2016, Cancer cell.

Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.

S. Deb, S. Deb, W. A. Yeudall, 2012, Carcinogenesis.

p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.

P. Graves, S. Deb, S. Deb, 2012, Archives of biochemistry and biophysics.

Allele specific gain-of-function activity of p53 mutants in lung cancer cells.

S. Deb, S. Deb, Shilpa Singh, 2012, Biochemical and biophysical research communications.

The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3

S. Grossman, S. Deb, S. Deb, 2021, Nature Communications.

The human oncoprotein MDM2 induces replication stress eliciting early intra-S-phase checkpoint response and inhibition of DNA replication origin firing

N. Mukhopadhyay, S. Grossman, S. Deb, 2013, Nucleic acids research.

Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites

S. Deb, S. Deb, B. Windle, 2014, Oncotarget.

Impact of surface chemistry and blocking strategies on DNA microarrays.

Anthony Guiseppi-Elie, Brad Windle, A. Guiseppi-Elie, 2003, Nucleic acids research.

Cellular Pathway Networking Using Gene Expression Profiles and Transcription Factor Binding Sites

B. Windle, Melanie Smith, Brad Windle, 2007 .